South Africa’s Aspen expands further into Asia with Sandoz China deal
ASPEN Pharmacare is expanding further into China through a deal to buy the Chinese business of Swiss group Sandoz for up to 92.6 million euros ($100.6 million), the South African company said. As part of the deal, Aspen Global Incorporated, a subsidiary of Aspen, will also buy the selling and intellectual property rights of a portfolio of established products that include Sandostatin, Aclasta and Voriconazole. The rights will also cover a pipeline of products to be launched by Sandoz China in the short to medium term. The deal "represents an attractive opportunity for Aspen to take a major step in its stated…